With our partner Salesforce, unify sales, marketing and customer service. Accele your growth!
The transition from basic research to marketable innovation remains one of the major challenges that France has trouble resolving. The agreement signed between the Institut Pasteur and Bpifrance intends to structure this process to accelerate the creation of startups from laboratories and strengthen the economic impact of scientific discoveries.
Last week, Yasmine Belkaid, Managing Director of the Institut Pasteur, and Nicolas Dufourcq, Managing Director of Bpifrancehave signed an agreement aimed at fluidifying technological transfer and intensifying the valuation of the results of public research. This partnership extends a collaboration initiated with the Innovio 2 Fund and the Startup Studio Argobio, and is part of the dynamics of the Deeptech planlaunched in 2019 to position France as a leading player in rupture technologies.
Transform research into viable companies
The development of Deeptech startups is based on a complex balance between scientific excellence, access to funding and industrial structuring. Many innovations remain confined to laboratories, for lack of a framework conducive to their entrepreneurial development. The partnership between the Pasteur and Bpifrance institute intends to remove these obstacles by bringing Support dedicated to researchers and project leaders.
Bpifrance will make available digital tools such as Tango and Tandem, designed to facilitate the connection between researchers and entrepreneurs. The objective is to promote the emergence of startups from the work carried out within the Pasteur Institute by ensuring them simplified access to funding and strategic support. Events, training sessions in entrepreneurship and support for funds will complete this ecosystem.
In return, the Pasteur Institute undertakes to promote these devices With its teams, to structure the identification of innovations with high potential and to facilitate their maturation in companies.
An issue of industrial and health sovereignty
The development of an efficient biotech ecosystem is a strategic issue. The transformation of medical discoveries into marketable innovations is not limited to the creation of startups: it engages the structuring of an industrial sector capable of supporting French competitiveness Faced with the North American and Asian poles.
The agreement thus provides for a Reinforcement of the network between startups, laboratories and industrialists In order to multiply technological transfers and facilitate the transition from research to the market. The stake is twofold: accelerate the development of new therapies, vaccines and diagnostic tools all in promoting the industrialization of innovations on the national territory.
A long -term dynamic
As part of the Deeptech plan, Bpifrance deploys a systemic approach aimed at Increase the flow of Deeptech startups, accelerate their scope and structure a lasting ecosystem. The partnership with the Institut Pasteur is part of this logic, with a clear ambition: Transform scientific research into an engine of economic and industrial development.
“” Without the intimate bond between basic research and innovation, science and progress, as we know them today, would simply not exist “Recalls Yasmine Belkaidciting Louis Pasteur. “”This partnership represents a decisive step in accelerating the development of diagnostic, therapeutic and vaccine solutions against infectious and emerging diseases. »»
